Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus nab-paclitaxel and gemcitabine in unresectable or metastatic pancreatic ductal adenocarcinoma
ChiCTR2400093744Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Dec 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Started Dec 2024; status: recruiting.
02
Drugs
cadonilimabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400093744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093744.